loading
전일 마감가:
$14.07
열려 있는:
$12.815
하루 거래량:
20.52M
Relative Volume:
2.95
시가총액:
$1.33B
수익:
$2.23B
순이익/손실:
$-248.39M
주가수익비율:
-5.0409
EPS:
-2.69
순현금흐름:
$-697.55M
1주 성능:
-29.69%
1개월 성능:
-32.67%
6개월 성능:
-88.42%
1년 성능:
-90.71%
1일 변동 폭
Value
$12.60
$13.95
1주일 범위
Value
$12.60
$22.86
52주 변동 폭
Value
$12.60
$150.48

사렙타 테라퓨틱스 Stock (SRPT) Company Profile

Name
명칭
Sarepta Therapeutics Inc
Name
전화
617-274-4000
Name
주소
215 FIRST STREET, CAMBRIDGE, MA
Name
직원
1,372
Name
트위터
@sarepta
Name
다음 수익 날짜
2024-11-06
Name
최신 SEC 제출 서류
Name
SRPT's Discussions on Twitter

SRPT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SRPT
Sarepta Therapeutics Inc
13.57 1.89B 2.23B -248.39M -697.55M -2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.19 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
549.00 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.08 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.47 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
290.93 27.29B 3.81B -644.79M -669.77M -6.24

사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-18 다운그레이드 Needham Buy → Hold
2025-06-20 다운그레이드 William Blair Outperform → Mkt Perform
2025-06-18 다운그레이드 TD Cowen Buy → Hold
2025-06-17 개시 Wolfe Research Peer Perform
2025-06-16 다운그레이드 BMO Capital Markets Outperform → Market Perform
2025-06-16 다운그레이드 BofA Securities Buy → Neutral
2025-06-16 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2025-06-16 다운그레이드 H.C. Wainwright Neutral → Sell
2025-06-16 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2025-06-16 다운그레이드 Piper Sandler Overweight → Neutral
2025-06-06 업그레이드 Scotiabank Sector Perform → Sector Outperform
2025-05-08 다운그레이드 Evercore ISI Outperform → In-line
2025-04-11 개시 Wells Fargo Overweight
2025-04-02 업그레이드 H.C. Wainwright Sell → Neutral
2025-03-31 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2025-02-11 개시 Deutsche Bank Hold
2024-11-27 재확인 Needham Buy
2024-11-25 개시 H.C. Wainwright Sell
2024-11-07 업그레이드 Cantor Fitzgerald Neutral → Overweight
2024-10-21 개시 Jefferies Buy
2024-10-10 재개 Raymond James Outperform
2024-07-29 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2024-06-26 다운그레이드 Citigroup Buy → Neutral
2024-05-31 개시 Piper Sandler Overweight
2024-05-28 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2024-05-14 업그레이드 Oppenheimer Perform → Outperform
2024-01-31 개시 BMO Capital Markets Outperform
2023-12-13 재개 Citigroup Buy
2023-12-12 개시 Deutsche Bank Buy
2023-11-21 개시 Wedbush Outperform
2023-10-31 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2023-10-31 다운그레이드 Oppenheimer Outperform → Perform
2023-06-23 다운그레이드 Evercore ISI Outperform → In-line
2023-04-26 개시 SMBC Nikko Outperform
2023-04-04 개시 Citigroup Buy
2023-03-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-12-22 재확인 BTIG Research Buy
2022-12-16 업그레이드 UBS Neutral → Buy
2022-04-04 재개 Cantor Fitzgerald Overweight
2022-01-05 재확인 Needham Buy
2021-12-09 업그레이드 Oppenheimer Perform → Outperform
2021-11-05 업그레이드 JP Morgan Neutral → Overweight
2021-09-15 업그레이드 Guggenheim Neutral → Buy
2021-08-05 업그레이드 JP Morgan Underweight → Neutral
2021-06-15 개시 BTIG Research Buy
2021-04-26 재개 Credit Suisse Neutral
2021-01-12 다운그레이드 Citigroup Buy → Neutral
2021-01-11 다운그레이드 UBS Buy → Neutral
2021-01-08 다운그레이드 JP Morgan Overweight → Underweight
2021-01-08 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-01-08 다운그레이드 Raymond James Outperform → Mkt Perform
2020-11-11 개시 Berenberg Hold
2020-10-28 개시 UBS Buy
2020-08-25 개시 Raymond James Outperform
2020-08-20 다운그레이드 Credit Suisse Outperform → Neutral
2020-03-31 개시 Mizuho Buy
2019-11-01 개시 Guggenheim Buy
2019-08-21 재확인 Needham Buy
2019-07-09 재확인 Morgan Stanley Overweight
2019-07-01 재확인 RBC Capital Mkts Outperform
2019-04-12 개시 Evercore ISI Outperform
2019-03-11 재확인 Credit Suisse Outperform
2018-10-12 개시 Bernstein Outperform
2018-10-01 개시 Cantor Fitzgerald Overweight
2018-09-26 재확인 RBC Capital Mkts Outperform
2018-09-14 재개 BofA/Merrill Buy
2018-09-06 개시 Credit Suisse Outperform
2018-08-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2018-06-21 재확인 Robert W. Baird Outperform
2018-06-20 재확인 Needham Buy
2018-06-19 재확인 H.C. Wainwright Buy
모두보기

사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스

pulisher
01:59 AM

Sarepta shares cut to $0 at H.C. Wainwright (SRPT:NASDAQ) - Seeking Alpha

01:59 AM
pulisher
12:43 PM

Navigating the Crossroads of Innovation and Safety: Assessing Sarepta Therapeutics in the Gene Therapy Landscape - AInvest

12:43 PM
pulisher
11:36 AM

Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy - Fierce Biotech

11:36 AM
pulisher
11:16 AM

SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program - Yahoo Finance

11:16 AM
pulisher
11:12 AM

Sarepta Is Worth $0 Amid ‘Unwinnable’ FDA Fight, Analyst Says - Bloomberg.com

11:12 AM
pulisher
10:42 AM

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market - Fierce Pharma

10:42 AM
pulisher
10:35 AM

Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug - Investopedia

10:35 AM
pulisher
10:22 AM

Sarepta's 'Unprecedented Times' Continue As Company Rebukes The FDA - Investor's Business Daily

10:22 AM
pulisher
10:15 AM

SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire

10:15 AM
pulisher
10:10 AM

Piper Sandler lowers Sarepta Therapeutics stock price target on Elevidys concerns - Investing.com

10:10 AM
pulisher
09:47 AM

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug - Yahoo Finance

09:47 AM
pulisher
09:32 AM

Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - TradingView

09:32 AM
pulisher
09:03 AM

Sarepta Stock Sinks. How Its Crisis Went From Bad to Worse. - Barron's

09:03 AM
pulisher
08:57 AM

Sarepta Therapeutics: Why Is SRPT Stock Crashing? - Forbes

08:57 AM
pulisher
08:45 AM

Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your RightsSRPT - Morningstar

08:45 AM
pulisher
07:54 AM

Sarepta Stands Ground Against HHS Request to Stop Elevidys Shipments - BioSpace

07:54 AM
pulisher
07:54 AM

Sarepta slides as FDA places clinical hold on gene therapy clinical trials (SRPT:NASDAQ) - Seeking Alpha

07:54 AM
pulisher
07:53 AM

Sarepta Therapeutics stock rating reiterated at Hold by TD Cowen - Investing.com

07:53 AM
pulisher
07:45 AM

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys - Benzinga

07:45 AM
pulisher
07:36 AM

SRPT DEADLINE REMINDER: Sarepta Therapeutics, Inc. Investors with Losses are Reminded to Contact BFA Law by the Upcoming August 25 Securities Fraud Deadline - Newsfile

07:36 AM
pulisher
07:33 AM

Sarepta Therapeutics stock price target slashed to $0 by H.C. Wainwright - Investing.com

07:33 AM
pulisher
06:57 AM

TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT) - StreetInsider

06:57 AM
pulisher
06:12 AM

Sarepta extends losses premarket after refusing FDA’s halt request (SRPT:NASDAQ) - Seeking Alpha

06:12 AM
pulisher
02:44 AM

Sarepta Therapeutics (NASDAQ:SRPT) Cut to “Hold” at Needham & Company LLC - Defense World

02:44 AM
pulisher
02:43 AM

Oppenheimer Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $41.00 - Defense World

02:43 AM
pulisher
02:43 AM

Bank of America Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $20.00 - Defense World

02:43 AM
pulisher
01:22 AM

Leerink Partnrs Has Pessimistic Outlook of SRPT Q2 Earnings - Defense World

01:22 AM
pulisher
12:17 PM

What drives Sarepta Therapeutics Inc. stock priceExceptional earning trajectories - PrintWeekIndia

12:17 PM
pulisher
Jul 20, 2025

Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Sarepta Therapeutics Inc. stockFree Stock Selection - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jul 20, 2025
pulisher
Jul 20, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

SRPT SECURITIES NEWS: Did Sarepta Therapeutics, Inc. - GlobeNewswire

Jul 20, 2025
pulisher
Jul 20, 2025

Q1 Earnings Estimate for SRPT Issued By Leerink Partnrs - Defense World

Jul 20, 2025
pulisher
Jul 20, 2025

Sarepta Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - Jammu Links News

Jul 20, 2025
pulisher
Jul 20, 2025

Sarepta Therapeutics’ (SRPT) Hold Rating Reiterated at Needham & Company LLC - Defense World

Jul 20, 2025
pulisher
Jul 20, 2025

StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies - Genetic Engineering and Biotechnology News

Jul 20, 2025
pulisher
Jul 19, 2025

This Gene Therapy Maker Refuses to Halt Shipments After Patient Deaths - Men's Journal

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline - Hoodline

Jul 19, 2025
pulisher
Jul 19, 2025

Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths - WTOP

Jul 19, 2025
pulisher
Jul 19, 2025

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths - Yahoo Finance

Jul 19, 2025
pulisher
Jul 19, 2025

Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths - U.S. News & World Report

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics lays off 500 employees amid FDA investigation, including 80 in Columbus - nbc4i.com

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta to continue Elevidys shipments despite FDA request to halt - Seeking Alpha

Jul 19, 2025
pulisher
Jul 19, 2025

Securities Fraud Litigation and Shareholder Returns: A Strategic Evaluation of Sarepta Therapeutics' ELEVIDYS Case - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

M&T Bank Corp Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics: A Sell Signal Amid Safety Crises and Existential Risks - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down Following Analyst Downgrade - Defense World

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 52-Week Low Following Analyst Downgrade - Defense World

Jul 19, 2025
pulisher
Jul 19, 2025

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys - Reuters

Jul 19, 2025

사렙타 테라퓨틱스 (SRPT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.67
price down icon 1.03%
$35.60
price up icon 0.17%
$102.58
price down icon 0.03%
$26.88
price up icon 1.05%
$110.44
price down icon 0.20%
biotechnology ONC
$290.46
price down icon 1.81%
자본화:     |  볼륨(24시간):